查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598780

不可切除的肝细胞癌市场：最终用户的全身治疗 - 全球预测 2025-2030

Unresectable Hepatocellular Carcinoma Market by Systemic Treatment (Chemotherapy, Immunotherapy, Molecularly Targeted Therapy), End User (Cancer Centers, Hospitals, Research institutes) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年不可切除的肝细胞癌市值为16.8亿美元，预计到2024年将达到19亿美元，复合年增长率为13.38%，到2030年将达到40.5亿美元。

不可切除的肝细胞癌（uHCC）是指因肿瘤大小、位置和患者健康状况等因素而无法手术切除的肝癌。全球肝癌发生率不断上升，加上肝炎感染、饮酒和非酒精性脂肪肝等因素，扩大了这个市场的范围。治疗是为了提高患者的寿命和生活品质而必需的，并且通常涉及全身疗法，例如免疫疗法、标靶药物和分子抑製剂，并且可在医院环境和专门的癌症护理中实际使用。这些治疗方法的需求是由新药发现的复杂性、医疗保健支出的增加以及诊断技术的改进所推动的。然而，高昂的治疗成本、有限的报销方案以及与当前疗法相关的显着副作用给市场成长带来了挑战。关键的成长要素之一是精准医学的进步，它为个人化治疗方法提供了巨大的潜力。特别是，治疗机会在于联合治疗的开发和使用人工智慧来客製化个别治疗计划。企业应投资大规模临床试验以提高治疗效果，并寻求策略联盟进行技术整合。然而，监管障碍、道德问题以及对更全面的患者资料的需求仍然是其限制。为了克服这些挑战并促进市场成长，需要研究更有效的生物标记识别和新型药物输送系统。另一方面，透过将新兴经济体纳入不断增加的医疗保健资金，区域市场扩张可能会成功。该市场仍然竞争激烈且前景广阔，对于愿意创新并能够有效应对监管环境的公司来说具有巨大的成长潜力。

主要市场统计
基准年[2023] 16.8亿美元
预测年份 [2024] 19亿美元
预测年份 [2030] 40.5亿美元
复合年增长率（%） 13.38%

市场动态：快速发展的不可切除肝细胞癌市场的关键市场洞察

供需的动态交互作用正在改变不可切除的肝细胞癌市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 肝癌发生率高
    • 肝癌患者增加
    • 化疗的主要用途
  • 市场限制因素
    • 不可切除的肝细胞癌的有限诊断
  • 市场机会
    • 新治疗方法的进展
  • 市场挑战
    • 目前治疗的效果有限

波特的五力策略工具引领不可切除的肝细胞癌市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对不可切除肝细胞癌市场的影响

外部宏观环境因素在塑造不可切除肝细胞癌市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解不可切除肝细胞癌市场的竞争状况

对不可切除肝细胞癌市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵不可切除肝细胞癌市场供应商绩效评估

FPNV 定位矩阵是评估不可切除肝细胞癌市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘不可切除肝细胞癌市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，不可切除的肝细胞癌市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肝癌发生率高
      • 肝癌增加
      • 化疗的主要应用
    • 抑制因素
      • 不可切除的肝细胞癌的有限诊断
    • 机会
      • 新疗法和疗法的进展
    • 任务
      • 目前治疗方法的边际效应
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 不可切除的肝细胞癌全身治疗市场

  • 化疗
  • 免疫疗法
  • 分子标靶治疗

第七章 不可切除的肝细胞癌市场：依最终使用者分类

  • 癌症中心
  • 医院
  • 调查机构
  • 专科诊所

第 8 章：美洲不可切除肝细胞癌市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第9章：亚太地区不可切除肝细胞癌市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲不可切除肝细胞癌市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Astrazeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co. Ltd
  • Eisai Co. Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline PLC
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharmaxis Ltd
  • Sanofi SA
  • Sumitomo Dainippon Pharma Co., Ltd
Product Code: MRR-742BD5184A85

The Unresectable Hepatocellular Carcinoma Market was valued at USD 1.68 billion in 2023, expected to reach USD 1.90 billion in 2024, and is projected to grow at a CAGR of 13.38%, to USD 4.05 billion by 2030.

Unresectable Hepatocellular Carcinoma (uHCC) refers to a form of liver cancer that cannot be surgically removed due to factors like tumor size, location, or patient health. This market's scope has grown due to increasing global liver cancer incidence tied to factors such as hepatitis infections, alcohol consumption, and non-alcoholic fatty liver disease. Treatments are necessitated by the need to improve patient longevity and quality of life, often involving systemic therapies like immunotherapy, targeted drugs, and molecular inhibitors, which represent substantial use within both hospital settings and specialized cancer treatment centers. The demand for these treatments is driven by the sophistication of new drug discoveries, increasing healthcare expenditure, and improving diagnostic techniques. However, market growth is challenged by high treatment costs, limited reimbursement scenarios, and significant side effects associated with current therapies. One key growth factor is the ongoing advancements in precision medicine, which offer tremendous potential for personalized treatment approaches. Opportunities lie particularly in the development of combination therapies and the use of Artificial Intelligence to tailor individual treatment plans. Companies should invest in extensive clinical trials to enhance treatment efficacy and seek strategic partnerships for technology integration. Meanwhile, regulatory hurdles, ethical concerns, and the need for more comprehensive patient data remain as limitations. To overcome these challenges and foster market growth, there's a need for research into more effective biomarker identification and novel drug delivery systems. Meanwhile, regional market expansion could thrive by tapping into emerging economies with increasing healthcare funding. The market's nature remains highly competitive yet promising, with significant growth prospects for enterprises willing to innovate and navigate the regulatory landscape effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 1.68 billion
Estimated Year [2024] USD 1.90 billion
Forecast Year [2030] USD 4.05 billion
CAGR (%) 13.38%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Unresectable Hepatocellular Carcinoma Market

The Unresectable Hepatocellular Carcinoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High incidence rate of liver carcinoma
    • Increasing cases of liver cancer
    • Major application of chemotherapy
  • Market Restraints
    • Limited diagnosis of unresectable hepatocellular carcinoma
  • Market Opportunities
    • Advancements for new treatment and therapies
  • Market Challenges
    • Limited effects of current therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Unresectable Hepatocellular Carcinoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Unresectable Hepatocellular Carcinoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Unresectable Hepatocellular Carcinoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Unresectable Hepatocellular Carcinoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Unresectable Hepatocellular Carcinoma Market

A detailed market share analysis in the Unresectable Hepatocellular Carcinoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Unresectable Hepatocellular Carcinoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Unresectable Hepatocellular Carcinoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Unresectable Hepatocellular Carcinoma Market

A strategic analysis of the Unresectable Hepatocellular Carcinoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Unresectable Hepatocellular Carcinoma Market, highlighting leading vendors and their innovative profiles. These include Astrazeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Chugai Pharmaceutical Co. Ltd, Eisai Co. Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Glaxosmithkline PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Pharmaxis Ltd, Sanofi S.A., and Sumitomo Dainippon Pharma Co., Ltd.

Market Segmentation & Coverage

This research report categorizes the Unresectable Hepatocellular Carcinoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Systemic Treatment, market is studied across Chemotherapy, Immunotherapy, and Molecularly Targeted Therapy.
  • Based on End User, market is studied across Cancer Centers, Hospitals, Research institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High incidence rate of liver carcinoma
      • 5.1.1.2. Increasing cases of liver cancer
      • 5.1.1.3. Major application of chemotherapy
    • 5.1.2. Restraints
      • 5.1.2.1. Limited diagnosis of unresectable hepatocellular carcinoma
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements for new treatment and therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited effects of current therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Unresectable Hepatocellular Carcinoma Market, by Systemic Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Molecularly Targeted Therapy

7. Unresectable Hepatocellular Carcinoma Market, by End User

  • 7.1. Introduction
  • 7.2. Cancer Centers
  • 7.3. Hospitals
  • 7.4. Research institutes
  • 7.5. Specialty Clinics

8. Americas Unresectable Hepatocellular Carcinoma Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Unresectable Hepatocellular Carcinoma Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Unresectable Hepatocellular Carcinoma Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astrazeneca PLC
  • 2. Bayer AG
  • 3. Bristol-Myers Squibb Company
  • 4. Celgene Corporation
  • 5. Chugai Pharmaceutical Co. Ltd
  • 6. Eisai Co. Ltd
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche Ltd
  • 9. Glaxosmithkline PLC
  • 10. Merck & Co. Inc.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Pharmaxis Ltd
  • 14. Sanofi S.A.
  • 15. Sumitomo Dainippon Pharma Co., Ltd

LIST OF FIGURES

  • FIGURE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET RESEARCH PROCESS
  • FIGURE 2. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET DYNAMICS
  • TABLE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MOLECULARLY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2023